To Validate the efficacy and safety of Safoof Suranjan Zafrani in Niqris (Gout)

Clinical Validation of Unani Pharmacopoeial formulation Safoof Suranjan Zafrani in Niqris (Gout)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/05/042542

Enrollment

110

Registered

2022-05-13

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M10- Gout

Interventions

Intervention1: Safoof suranjan zafrani: 2.5 gm of Safoof suranjan zafrani in the form of powder will be given twice a day orally with water for 6 weeks. Control Intervention1: Not Applicable: Nil

Eligibility

Inclusion criteria

Inclusion criteria: 1.Confirmed diagnosis of gout meeting ACR CRITERIA. 2.Assymetric swelling within a joint. 3.First metatarsophalangeal joint tender or swollen. 4.Hyperuricemia. 5.Maximal inflammation developed within one day 6. Monoarthritis attack 7. More than one acute arthritis attack 8.Redness over joint 9. Subcortical cysts without erosion on x-ray 10. Suspected tophi 11.Synovial fluid culture negavtive for organism during aute attack. 12.Unilateral first metatarsophalangeal joint attack. 13.Unilateral tarsal joint attack.

Exclusion criteria

Exclusion criteria: 1. Clinical conditions involving joints e.g.Osteoarthritis, Rheumatoid Arthritis, Rheumatic arthritis 2. Patients having any systemic diseases such as hypertension, diabetes mellitus, cardiovascular or cerebrovascular diseases, Hepatic and renal disease, Osteomalacia, Osteoporosis 3. Patients with recent h/o Dengue, chikungunya and viral fever 4.Grade-2 obesity(BMI >35) 5.Patients on long term medications. 6. Patients taking drugs which increased serum uric acid levels(Thiazide Diuretics etc) and decreased serum calcium levels (furosemide,etc) 7.Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
Reduction in signs and symptoms of Gout.Timepoint: 6 weeks	—

Secondary

Measure	Time frame
Reduction in Serum Uric Acid level.Timepoint: 6 weeks	—

Countries

India

Contacts

Public ContactDr Arsheed Iqbal

Regional research Institute of Unani Medicine ,Srinagar(CCRUM Ministry of AYUSH)

drarsheediqbal@gmail.com9419078302

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026